Dr. Sara Hurvitz, MD
Claim this profileUCLA Medical Center / David Geffen School of Medicine
Expert in Breast Cancer
Studies Tumors
17 reported clinical trials
24 drugs studied
About Sara Hurvitz, MD
Education:
- Obtained BS in Biology and BA in Psychology from the University of California, Irvine (1993).
- Earned MD from the Keck School of Medicine at the University of Southern California (1999).
Experience:
- Completed Internal Medicine Internship and Residency at UCLA (2002).
- Finished Hematology/Oncology Fellowship at UCLA (2006).
- Since 2006, has been a faculty member at UCLA, directing the Breast Oncology Program and serving as the medical director of the Clinical Research Unit for UCLA's Jonsson Comprehensive Cancer Center.
- Appointed Senior Vice President of the Clinical Research Division at Fred Hutch and Head of the Division of Hematology and Oncology at the University of Washington Department of Medicine (since 2023).
Area of expertise
1Breast Cancer
Global LeaderStage IV
HER2
Stage III
2Tumors
HER2
Stage IV
Stage III
Affiliated Hospitals
Clinical Trials Sara Hurvitz, MD is currently running
ARX788
for HER2-Positive Breast Cancer
This trial tests ARX788, a new IV medicine, for patients with HER2-positive metastatic breast cancer who did not respond well to T-DXd. The medicine targets a specific protein on cancer cells to help stop their growth.
Recruiting1 award Phase 28 criteria
Trastuzumab Deruxtecan + Anastrozole
for Breast Cancer
This phase II trial investigates how well trastuzumab deruxtecan works alone or in combination with anastrozole in treating patients with HER2 low, hormone receptor positive breast cancer. Trastuzumab deruxtecan is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug called deruxtecan. Trastuzumab attaches to HER2 expressed at low levels on cancer cells in a targeted way and delivers deruxtecan to kill them. Anastrozole works by decreasing estrogen production and suppressing the growth of tumors that need estrogen to grow. This study is evaluating how effective trastuzumab deruxtecan is at treating hormone receptor positive cancer cells that have low levels of HER2 expressed on them when given alone or in combination with anastrozole.
Recruiting1 award Phase 221 criteria
More about Sara Hurvitz, MD
Clinical Trial Related2 years of experience running clinical trials · Led 17 trials as a Principal Investigator · 4 Active Clinical TrialsTreatments Sara Hurvitz, MD has experience with
- Abemaciclib
- Placebo
- Tucatinib
- Trastuzumab Deruxtecan
- Fulvestrant
- ARX788
Breakdown of trials Sara Hurvitz, MD has run
Breast Cancer
Tumors
Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Sara Hurvitz, MD specialize in?
Sara Hurvitz, MD focuses on Breast Cancer and Tumors. In particular, much of their work with Breast Cancer has involved Stage IV patients, or patients who are HER2.
Is Sara Hurvitz, MD currently recruiting for clinical trials?
Yes, Sara Hurvitz, MD is currently recruiting for 3 clinical trials in Santa Monica California. If you're interested in participating, you should apply.
Are there any treatments that Sara Hurvitz, MD has studied deeply?
Yes, Sara Hurvitz, MD has studied treatments such as Abemaciclib, Placebo, Tucatinib.
What is the best way to schedule an appointment with Sara Hurvitz, MD?
Apply for one of the trials that Sara Hurvitz, MD is conducting.
What is the office address of Sara Hurvitz, MD?
The office of Sara Hurvitz, MD is located at: UCLA Medical Center / David Geffen School of Medicine, Santa Monica, California 90404 United States. This is the address for their practice at the UCLA Medical Center / David Geffen School of Medicine.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.